TYMP and neoplasm: Here, we tested the immunomodulatory effects of the TYMP inhibitor tipiracil hydrochloride (TPI), alone and in combination with a TLR7 agonist (imiquimod), activated whole tumor lysate-pulsed DCs (IMQDC-Ag), both in vitro and in vivo.